Prostate cancer breakthrough

The research, indicates that the drug could treat the most aggressive type of prostate cancer when it has spread. Abiraterone was found to shrink tumours and lead to dramatic falls in prostate specific antigen (PSA) levels in up to 80% of advanced prostate cancer patients.

John Neate, chief executive of The Prostate Cancer Charity said: “This is an exciting development. Advanced prostate cancer is very difficult to treat as, it stops responding to conventional ways of controlling testosterone, essential to the cancer’s continued growth.”